Parkinson’s cell therapy developer Aspen Neuroscience on Thursday evening

帕金森病细胞疗法开发商 Aspen Neuroscience 于周四晚间

its initial public offering

其首次公开募股

, raising $140.6

，筹集资金1.406亿美元

million to take its treatment deeper into clinical testing.

百万美元用于将其治疗方案推进至更深入的临床试验阶段。

Aspen sold roughly 9.4 million shares at $15 each,

阿斯彭以每股15美元的价格出售了约940万股股票，

on the low end of the price range it pitched

在其定价区间的低端

and will make its Wall Street debut Friday under the ticker symbol “ASPE.”

并将于周五以股票代码“ASPE”在华尔街首次亮相。

Aspen claims its cell therapy

阿斯彭声称其细胞疗法

could address an unmet need in Parkinson’s, a condition in which the destruction of dopamine-producing brain cells leads to trouble walking, talking and completing everyday tasks. For decades, people with Parkinson's have relied on dopamine-replacement therapies like levodopa to help control symptoms.

有望满足帕金森病领域尚未被满足的需求。帕金森病是一种因产生多巴胺的脑细胞受损而导致行走、言语和完成日常任务出现困难的疾病。数十年来，帕金森病患者一直依赖左旋多巴等多巴胺替代疗法来帮助控制症状。

But these treatments don’t replace lost neurons or “slow continued neuronal degeneration,” Aspen said in its IPO filing. .

但阿斯彭在其首次公开募股（IPO）文件中表示，这些疗法并不能替代丢失的神经元，也无法“减缓持续的神经元退化”。

Aspen’s solution, “sasineprocel,” is a one-time treatment designed to replenish dopamine-making cells. The company harvests cell samples from a patient’s skin and modifies them to become a type of stem cell. Aspen then turns those cells into “precursor cells” that eventually mature into dopamine-producing neurons when they’re re-introduced into a patient.

阿斯彭公司的解决方案“sasineprocel”是一种一次性疗法，旨在补充产生多巴胺的细胞。该公司从患者皮肤中采集细胞样本，并将其改造为一种干细胞。随后，阿斯彭将这些细胞转化为“前体细胞”，当重新植入患者体内时，这些前体细胞最终会成熟为产生多巴胺的神经元。

This approach holds the potential to “slow or halt” disease progression, Aspen said..

阿斯彭表示，这种方法有望“减缓或阻止”疾病进展。

The company is testing

该公司正在测试

sasineprocel

sasineprocel

in an open-label Phase 1/2a study of patients with mid-stage or “moderately advanced” Parkinson’s disease.

在一项针对中期或“中度进展期”帕金森病患者的开放标签1/2a期研究中。

Early trial data

早期试验数据

suggested potential improvements in function along with a favorable safety profile. Long-term data from that study are expected in 2028, but Aspen intends to launch a Phase 3 study beforehand, by the end of next year.

提示在功能方面存在潜在的改进，同时具有良好的安全性特征。该研究的长期数据预计将于2028年公布，但Aspen计划在明年年底之前启动一项III期研究。

A second experimental cell therapy for a group of rare brain disorders called pediatric leukodystrophies will soon enter preclinical studies, according to the biotech.

据该生物科技公司称，第二种针对一组被称为儿童脑白质营养不良的罕见脑部疾病的实验性细胞疗法即将进入临床前研究阶段。

Aspen is one of a few companies working on

阿斯彭是少数几家致力于

cell therapies for Parkinson’s

帕金森病的细胞疗法

. Bayer subsidiary BlueRock Therapeutics has a therapy

拜耳子公司BlueRock Therapeutics拥有一种疗法

in Phase 3 testing

在第三期临床试验中

. Others including

. 其他包括

Oryon Cell Therapies

Oryon细胞疗法

,

，

XellSmart

XellSmart

and

和

Cellular Intelligence

细胞智能

— which acquired a treatment from Novo — have prospects in development, too.

——从诺和诺德获得了一项治疗技术——在开发方面也颇具前景。

Some of those treatments are made from the cells of donors instead of individual patients. Aspen claimed its personalized approach could be safer than these donor-derived therapies, which involve a lengthy course of immunosuppressive drugs after treatment. Some preclinical data has indicated that a patient-specific therapy might also produce longer-lasting effects, the company said. .

其中一些疗法是由捐赠者的细胞制成，而非来自个体患者。阿斯彭公司声称，其个性化方法可能比这些源自捐赠者的疗法更安全，后者在治疗后需要长期使用免疫抑制药物。该公司表示，一些临床前数据表明，针对特定患者的疗法还可能产生更持久的疗效。

Most of the companies to go public this year have had experimental drugs in mid-stage testing or later at the time of their offerings. With Aspen’s debut, though, nine biotechs with medicines in Phase 1 development have priced share sales in 2026, too — more than the previous two years combined, according to .

今年上市的大多数公司在发行时，其实验性药物已处于中期或后期临床试验阶段。然而，随着阿斯彭的首次公开募股，2026年已有九家生物科技公司将其处于一期临床试验阶段的药物作为卖点进行定价发售——据称，这一数量超过了前两年的总和。

BioPharma Dive data

BioPharma Dive 数据

.

。

The average IPO haul this year has also been considerably higher than in recent years, with 17 companies raising at least $250 million, data show. But cell and gene therapy makers, which have accounted for only a handful of offerings since 2024, haven’t yet seen that kind of interest. Scribe Therapeutics, the only other genetic medicine developer to go public this year, .

数据显示，今年首次公开募股（IPO）的平均融资额也远高于近年水平，共有17家公司募资至少2.5亿美元。但自2024年以来仅推出少数几次发行的细胞和基因疗法制造商尚未获得此类关注。Scribe Therapeutics是今年唯一一家上市的基因药物开发商。

banked about $129 million

获利约1.29亿美元

in its August IPO.

在其8月的首次公开募股（IPO）中。

Twenty-nine biotechs have now gone public on U.S. stock exchanges in 2026, the most in a single year since 2021.

2026年，已有29家生物科技公司在美国证券交易所上市，创2021年以来单年最高纪录。